Clozapine for Management of Neuropsychiatric Symptoms in Dementia with Lewy Bodies: Case Report and Literature Review

Overview

Journal Can J Hosp Pharm

Date 2023 Sep 28

PMID 37767388

Authors

Nikoo Hashemi

Dean Yang

David Shergold

Gayla Tennen

Chris Fan-Lun

Affiliations

Soon will be listed here.

References

BURKE W, Pfeiffer R, McComb R . Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci. 1998; 10(2):227-9. DOI: 10.1176/jnp.10.2.227. View

Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A . Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2013; 383(9916):533-40. DOI: 10.1016/S0140-6736(13)62106-6. View

HONIGFELD G, Arellano F, Sethi J, Bianchini A, Schein J . Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998; 59 Suppl 3:3-7. View

Vann Jones S, OBrien J . The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2013; 44(4):673-83. DOI: 10.1017/S0033291713000494. View

Watts K, Storr N, Barr P, Rajkumar A . Systematic review of pharmacological interventions for people with Lewy body dementia. Aging Ment Health. 2022; 27(2):203-216. DOI: 10.1080/13607863.2022.2032601. View

Lee H, Hanner J, Yokley J, Appleby B, Hurowitz L, Lyketsos C . Clozapine for treatment-resistant agitation in dementia. J Geriatr Psychiatry Neurol. 2007; 20(3):178-82. DOI: 10.1177/0891988707303335. View

Tampi R, Tampi D, Young J, Balachandran S, Hoq R, Manikkara G . Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis. World J Psychiatry. 2019; 9(3):47-54. PMC: 6560499. DOI: 10.5498/wjp.v9.i3.47. View

Seppi K, Chaudhuri K, Coelho M, Fox S, Katzenschlager R, Perez Lloret S . Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord. 2019; 34(2):180-198. PMC: 6916382. DOI: 10.1002/mds.27602. View

Bhamra M, Rajkumar A, Ffytche D, Kalafatis C . Successful management of persistent distressing neuropsychiatric symptoms by clozapine in a patient suffering from dementia with Lewy bodies. BMJ Case Rep. 2018; 2018. PMC: 6067144. DOI: 10.1136/bcr-2018-224710. View

10.

Archie A, Persoons P, Vandenbulcke M . [The use of clozapine and levodopa for the treatment of persistent visual hallucinations and parkinsonism in Lewy body dementia]. Tijdschr Psychiatr. 2013; 55(4):287-91. View

11.

Komaragiri A, Friedman J . Multiple re-challenges for clozapine neutropenia in Parkinson's disease. Parkinsonism Relat Disord. 2016; 23:114-5. DOI: 10.1016/j.parkreldis.2015.12.009. View

12.

Merims D, Balas M, Peretz C, Shabtai H, Giladi N . Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol. 2006; 29(6):331-7. DOI: 10.1097/01.WNF.0000236769.31279.19. View

13.

Taylor J, McKeith I, Burn D, Boeve B, Weintraub D, Bamford C . New evidence on the management of Lewy body dementia. Lancet Neurol. 2019; 19(2):157-169. PMC: 7017451. DOI: 10.1016/S1474-4422(19)30153-X. View

14.

McKeith I, Boeve B, Dickson D, Halliday G, Taylor J, Weintraub D . Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1):88-100. PMC: 5496518. DOI: 10.1212/WNL.0000000000004058. View

15.

Majic T, Mell T, Heinz A, Rapp M . Adjunct treatment with levodopa in a patient with dementia with Lewy bodies, delusions and severe neuroleptic hypersensitivity syndrome. Int Psychogeriatr. 2010; 22(4):678-9. DOI: 10.1017/S1041610210000190. View

16.

Walker Z, Possin K, Boeve B, Aarsland D . Lewy body dementias. Lancet. 2015; 386(10004):1683-97. PMC: 5792067. DOI: 10.1016/S0140-6736(15)00462-6. View

17.

Tripathi A, Gupta P, Bansal T . Management of Psychiatric Disorders in Patients with Parkinson's Diseases. Indian J Psychiatry. 2022; 64(Suppl 2):S330-S343. PMC: 9122177. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_29_22. View

18.

Kapur S, Seeman P . Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001; 158(3):360-9. DOI: 10.1176/appi.ajp.158.3.360. View

19.

Geroldi C, Frisoni G, Bianchetti A, Trabucchi M . Drug treatment in Lewy body dementia. Dement Geriatr Cogn Disord. 1997; 8(3):188-97. DOI: 10.1159/000106630. View

20.

Goldman J, Holden S . Treatment of psychosis and dementia in Parkinson's disease. Curr Treat Options Neurol. 2014; 16(3):281. PMC: 3994190. DOI: 10.1007/s11940-013-0281-2. View